Also in post hoc analysis, indicators of organ damage including creatinine elevation, troponin I or T, and elevated LDH showed a trend toward improvement in the mean time to resolution of these markers in the caplacizumab group when compared with placebo.
← all excerpts
Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.
1
—
—